Welcome to our dedicated page for LIGAND PHARMACEUTICALS SEC filings (Ticker: LGNZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on LIGAND PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into LIGAND PHARMACEUTICALS's regulatory disclosures and financial reporting.
Ligand Pharmaceuticals Incorporated reported that it entered into a Third Amendment to its existing credit agreement with Citibank and other lenders. The amendment extends the loan’s maturity date to September 12, 2028, giving the company more time before the debt comes due.
The amendment also tightens a key financial test. Ligand must maintain at least $55 million of consolidated EBITDA for the trailing four-quarter period ending September 30, 2025 and for each trailing four-quarter period after that. This sets a clear performance threshold the company needs to meet to stay in compliance with its credit facility.